Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohns disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective.Common side effects include headache, nausea, abdominal pain, and fever. Serious side effects may include pericarditis, liver problems, and kidney problems. Use in pregnancy and breastfeeding appears safe. In people with a sulfa allergy certain formulations may result in problems. Mesalazine is an aminosalicylate and anti-inflammatory. It works by direct contact with the intestines.Mesalazine was approved for medical use in the United States in 1987. It is on the World Health Organizations List of Essential Medicines. It is available as a generic medication and sold under many brand names worldwide. In 2019, it was the 229th most commonly prescribed medication in the United States, with more than 2 million prescriptions. Medical uses
It is used to treat inflammatory bowel disease, including ulcerative colitis and Crohns disease (effective only in colonic diseases). It is generally used for mildly to moderately active disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective. Side effects
There are no data on use in pregnant women, but the drug does cross the placenta and is excreted in breast milk.
Sonidegib (INN), sold under the brand name Odomzo, is a medication used to treat cancer.Sonidegib is Hedgehog signaling pathway inhibitor (via smoothened antagonism). Approvals and indications
It was approved for medical use in the United States and in the European Union in 2015It is indicated for the treatment of adults with locally advanced basal-cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. Pharmacology
Sonidegib is administered by mouth. Common side effects include muscle spasms, hair loss, fatigue, abdominal pain, nausea, headache, and weight loss.Sonidegib binds to and inhibits smoothened to inhibit activation of the Hedgehog pathway. Sonidegib is primarily metabolized by CYP3A and is eliminated hepatically. Development
It has been investigated as a potential treatment for:

Pancreatic cancer
Breast cancer
Basal cell carcinoma of the skin
Small cell lung cancer
Medulloblastoma
Advanced solid tumors (including ovarian, breast, pancreatic, stomach, oesophageal cancers and glioblastoma multiforme)
Acute leukemia and chronic myeloid leukemia
Myelofibrosis and essential thrombocythaemiaIt has demonstrated significant efficacy against melanoma in vitro and in vivo. It also demonstrated efficacy in a mouse model of pancreatic cancer. References
External links
"Sonidegib". Drug Information Portal. U.S. National Library of Medicine. "Sonidegib phosphate". Drug Information Portal. U.S. National Library of Medicine.